OGEN

Oragenics, Inc. (ORAGENICS INC) - 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for the period ended September 30, 2010. Oragenics, Inc. is a biopharmaceutical company focused on oral health products (ProBiora3, SMaRT Replacement Therapy) and novel antibiotics (MU1140-S). The company is a smaller reporting company incorporated in Florida. As of November 1, 2010, there were 5,663,076 shares of Common Stock outstanding following a 20-for-1 reverse stock split effective September 24, 2010.

Key Financial Metrics

Note: Working Capital calculated as Total Current Assets ($2,413,413) minus Total Current Liabilities ($2,465,027).

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 82.6% for the three months ended September 30, 2010, compared to the same period in 2009, driven primarily by increased sales of ProBiora3 products. For the nine months, revenue increased 176% to $1.01 million.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 39.4% in the quarter and 23.4% for the nine months, attributed to increased marketing, salaries, and stock-based compensation.
• Loss Expansion: Net loss increased to $1.88 million for the quarter and $5.63 million for the nine months, compared to $1.44 million and $4.29 million in the prior year periods, respectively.
• Liquidity Shift: The company moved from positive working capital of $2.56 million at year-end 2009 to a negative working capital position of approximately $51,600 at September 30, 2010. Restricted cash decreased significantly from $2.45 million to $555,147 as funds were released for operations.
• Debt Financing: The company entered into a $2.0 million revolving credit facility with the Koski Family Limited Partnership (KFLP). As of the filing date, the full $2.0 million had been drawn down.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows. Management states that existing cash, credit facility borrowings, and grant funds are expected to fund operations through the end of 2010, but additional financing is required thereafter.
• Grant Funding: On November 1, 2010, the company received notification of a $733,437 federal grant award under the Qualifying Therapeutic Discovery Project. $371,219 is expected in November 2010, with the remainder by early 2011.
• Capital Raising: The company recorded $459,030 in prepaid offering expenses related to ongoing capital raise efforts. If the offering fails, these will be expensed.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2010, due to material weaknesses including limited documentation, insufficient personnel for segregation of duties, and lack of formal written policies.
• Product Pipeline: The company expects to commence a second Phase 1 clinical trial for SMaRT Replacement Therapy in 2011 and file an IND application for MU1140-S in 2011.

Investor Verification Checklist

• Verify the status and terms of the $2.0 million revolving credit facility with KFLP, including interest rates (LIBOR + 6.0%) and maturity (July 30, 2011).
• Confirm the receipt and timing of the $733,437 federal grant award and its impact on cash flow projections.
• Assess the success of the ongoing capital raise efforts to determine if the $459,030 in prepaid offering expenses will be capitalized or expensed.
• Review the remediation plan for material weaknesses in internal controls over financial reporting.
• Monitor the burn rate of cash and cash equivalents ($505,215) against the negative operating cash flow of $4.68 million for the nine-month period.
• Validate the sustainability of ProBiora3 revenue growth and the impact of product returns/allowances on net revenue.